問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Urology

Division of General Surgery

Division of Hematology & Oncology

更新時間：2024-06-13

楊晨洸Yang, Cheng-Kuang
  • Principal Investigator
  • Clinical Trial Experience (year)

  • gu5121@vghtc.gov.tw

Recruiting Trial

50Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊晨洸

List

91Cases

2022-04-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2020-10-16 - 2028-06-26

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-06-30 - 2032-05-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-05-19 - 2027-01-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-12-30 - 2031-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2015-01-01 - 2018-12-31

Phase III

A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY

  • Condition/Disease

    Urothelial Bladder Cancer

  • Test Drug

    TECENTRIQ® (Atezolizumab)

Participate Sites
4Sites

Terminated4Sites

2017-02-01 - 2023-02-28

Phase III

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Atezolizumab

Participate Sites
6Sites

Terminated5Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-04-10 - 2019-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (AntiPD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Condition/Disease

    UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Test Drug

    Atezolizumab

Participate Sites
3Sites

Terminated3Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of General Surgery

2011-03-15 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

1 5 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB